CagriSema Demonstrates Significant Weight Loss in Adults with Obesity
illi News/10304408

Trending...
CHICAGO, June 22, 2025 ~ A new dual agonist, CagriSema, has shown promising results in improving weight loss for patients with and without type 2 diabetes who have overweight or obesity. The findings were presented at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in the New England Journal of Medicine.

According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.

CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.

More on illi News
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.

Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.

More on illi News
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.

Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.

The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.

The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on illi News